ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
Health & Biotech
Health & Biotech
Link copied to
AdAlta (ASX:1AD) has received an Indian patent for its lead program, AD-214.
The new patent protects the i-body sequence used in AD-214, as well as its pharmaceutical compositions and derivatives.
India is now the sixth country to grant a patent for AD-214 after Australia, the US, Japan, China and Singapore.
The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed.
“India is a significant pharmaceutical market in its own right, and is also a leading manufacturing location for biologic drugs and biosimilars,” commented AdAlta’s CEO, Dr Tim Oldham.
“This patent expands the protected market for AD-214, and provides additional security for AD-214’s global supply chain.”
The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer.
According to the latest data from Grandview Research, the market is about to explode from US$1 billion in 2020 to US$20.3 billion by 2028, with two million patients in 10 years.
Wearable nasal and respiratory tech company, Rhinomed (ASX:RNO), has signed a supply deal with BTNX Inc, one of Canada’s largest manufacturers of rapid antigen test (RAT) kits.
The deal covers the supply of Rhinoswab and Rhinoswab Junior for inclusion in BTNX’s range of Covid-19 RAT kits.
The Rhinoswab Junior kit is one of the world’s first RAT kits designed for children.
The agreement will last for an initial period of 24 months, and will require BTNX to purchase 22.5 million swabs during this period staring in July.